Gene therapy could save and improve lives, but at $2 million per treatment, it’s out of reach for the most vulnerable of cases. CVS Health plans to make the therapy accessible through employer-sponsored insurance.
The healthcare company is leveraging its 2018 acquisition of health insurance company Aetna to spread out the cost of treatment, according to a white paper published by the company this week. CVS Health also plans to launch a new insurance product by the end of March to absorb the financial risk of covering these therapies.
